Compare Stocks: BDRX, APVO, GNPX, and CRIS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.82	$3.43	$1.37 ▼ $48.78	$3.29M	1.6	201,023 shs	43,577 shs
BDRX Biodexa Pharmaceuticals	$1.30	$1.52	$0.61 ▼ $59.40	$1.34M	1.18	8.14 million shs	141.43 million shs
CRIS Curis	$1.13	$3.23	$1.11 ▼ $38.60	$2.36M	3.01	147,618 shs	128,305 shs
GNPX Genprex	$3.35	$6.11	$3.31 ▼ $1,210.00	$2.75M	-0.94	292,459 shs	27,693 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	0.00%	+4.60%	-38.10%	-61.28%	-93.12%
BDRX Biodexa Pharmaceuticals	0.00%	+53.30%	-14.47%	-57.65%	-95.68%
CRIS Curis	0.00%	-16.30%	-37.22%	-86.41%	-96.90%
GNPX Genprex	0.00%	-4.29%	-22.45%	-68.71%	-98.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.82	$3.43	$1.37 ▼ $48.78	$3.29M	1.6	201,023 shs	43,577 shs
BDRX Biodexa Pharmaceuticals	$1.30	$1.52	$0.61 ▼ $59.40	$1.34M	1.18	8.14 million shs	141.43 million shs
CRIS Curis	$1.13	$3.23	$1.11 ▼ $38.60	$2.36M	3.01	147,618 shs	128,305 shs
GNPX Genprex	$3.35	$6.11	$3.31 ▼ $1,210.00	$2.75M	-0.94	292,459 shs	27,693 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	0.00%	+4.60%	-38.10%	-61.28%	-93.12%
BDRX Biodexa Pharmaceuticals	0.00%	+53.30%	-14.47%	-57.65%	-95.68%
CRIS Curis	0.00%	-16.30%	-37.22%	-86.41%	-96.90%
GNPX Genprex	0.00%	-4.29%	-22.45%	-68.71%	-98.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APVO Aptevo Therapeutics	2.33	Hold	N/A	N/A
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
CRIS Curis	2.00	Hold	$43.00	3,705.31% Upside
GNPX Genprex	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BDRX, APVO, GNPX, and CRIS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/9/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/17/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/29/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/24/2026	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $43.00
7/17/2026	CRIS Curis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GNPX Genprex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	CRIS Curis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/1/2026	APVO Aptevo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	$17.42 per share	N/A
BDRX Biodexa Pharmaceuticals	$470K	2.85	N/A	N/A	$110.30 per share	0.01
CRIS Curis	$9.44M	0.25	N/A	N/A	$8.45 per share	0.13
GNPX Genprex	N/A	N/A	N/A	N/A	$53.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APVO Aptevo Therapeutics	-$25.97M	-$51.83	N/A	N/A	N/A	N/A	-201.49%	-119.21%	11/5/2026 (Estimated)
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRIS Curis	-$7.58M	-$14.22	N/A	N/A	N/A	-80.29%	-2,365.94%	-200.88%	11/5/2026 (Estimated)
GNPX Genprex	-$16.23M	-$133.36	N/A	N/A	N/A	N/A	-163.12%	-128.98%	12/2/2026 (Estimated)

Latest BDRX, APVO, GNPX, and CRIS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	APVO Aptevo Therapeutics	-$6.0150	-$5.31	+$0.7050	-$5.31	N/A	N/A
8/14/2026	Q2 2026	CRIS Curis	-$6.95	-$4.02	+$2.93	-$4.02	$1.00 million	N/A
8/14/2026	Q2 2026	GNPX Genprex	N/A	-$9.40	N/A	-$9.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APVO Aptevo Therapeutics	N/A	2.08	2.08
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
CRIS Curis	N/A	0.49	0.49
GNPX Genprex	N/A	6.76	6.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APVO Aptevo Therapeutics	8.06%
BDRX Biodexa Pharmaceuticals	17.51%
CRIS Curis	29.97%
GNPX Genprex	14.05%

Insider Ownership

Company	Insider Ownership
APVO Aptevo Therapeutics	0.37%
BDRX Biodexa Pharmaceuticals	0.34%
CRIS Curis	5.78%
GNPX Genprex	0.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APVO Aptevo Therapeutics	50	1.81 million	1.80 million	Not Optionable
BDRX Biodexa Pharmaceuticals	20	1.03 million	1.03 million	Not Optionable
CRIS Curis	60	2.09 million	1.97 million	No Data
GNPX Genprex	20	820,000	818,000	No Data

BDRX, APVO, GNPX, and CRIS Headlines

Recent News About These Companies

Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | prnewswire.com

Genprex advances AAV diabetes gene therapy manufacturing

August 18, 2026 | tipranks.com

Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy

August 18, 2026 | prnewswire.com

Lung cancer gene therapy takes first step toward AI biomarker selection

August 3, 2026 | msn.com

Genprex shares rise after collaboration with Roche Diagnostics

August 3, 2026 | msn.com

Genprex, Roche Partner on NSCLC Biomarker Validation

August 3, 2026 | tipranks.com

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

August 3, 2026 | prnewswire.com

Genprex Granted Nasdaq Listing Exception Amid Compliance Push

July 30, 2026 | tipranks.com

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

July 27, 2026 | businesswire.com

Genprex Inc

July 24, 2026 | cnn.com

Genprex Announces Reverse Stock Split Amid Nasdaq Compliance Push

July 15, 2026 | tipranks.com

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 ...

June 22, 2026 | finance.yahoo.com

Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy

June 22, 2026 | tipranks.com

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer

June 22, 2026 | prnewswire.com

Genprex Shareholders Approve Expanded Equity Plan, Reverse Split

June 18, 2026 | tipranks.com

Genprex to Participate at BIO International Convention 2026

June 17, 2026 | prnewswire.com

Genprex Faces Nasdaq Delisting Notice, Plans Compliance Steps

June 12, 2026 | tipranks.com

Genprex Highlights Biomarker Data for Reqorsa Lung Cancer Therapy

May 26, 2026 | tipranks.com

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 26, 2026 | prnewswire.com

GNPX Share News Today

May 15, 2026 | uk.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, APVO, GNPX, and CRIS Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

$1.82 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.85 +0.03 (+1.87%)

As of 06:14 AM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.30 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.16 -0.14 (-10.38%)

As of 06:25 AM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Curis NASDAQ:CRIS

$1.13 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.13 +0.00 (+0.09%)

As of 06:00 AM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Genprex NASDAQ:GNPX

$3.35 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.28 -0.07 (-2.09%)

As of 06:07 AM Eastern

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, APVO, GNPX, and CRIS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, APVO, GNPX, and CRIS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, APVO, GNPX, and CRIS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, APVO, GNPX, and CRIS Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

Biodexa Pharmaceuticals NASDAQ:BDRX

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, APVO, GNPX, and CRIS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, APVO, GNPX, and CRIS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, APVO, GNPX, and CRIS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, APVO, GNPX, and CRIS Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

Biodexa Pharmaceuticals NASDAQ:BDRX

Curis NASDAQ:CRIS

Genprex NASDAQ:GNPX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools